2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Microenvironment contributes to follicular lymphoma (FL) pathogenesis and impacts survival with macrophages playing a controversial role. In the present study, using FL primary samples and HK follicular dendritic cells (FDC) to mimic the germinal center, together with mouse models, we have analyzed the three-way crosstalk of FL-FDC-macrophages and derived therapeutic opportunities. Ex vivo primary FL-FDC co-cultures ( n = 19) and in vivo mouse co-xenografts demonstrated that FL-FDC crosstalk favors tumor growth and, via the secretion of CCL2 and CSF-1, promotes monocyte recruitment, differentiation, and polarization towards an M2-like protumoral phenotype. Moreover, FL-M2 co-cultures displayed enhanced angiogenesis, dissemination, and immunosuppression. Analysis of the CSF-1/CSF-1R pathway uncovered that CSF-1 was significantly higher in serum from grade 3A FL patients, and that high CSF-1R expression in FL biopsies correlated with grade 3A, reduced overall survival and risk of transformation. Furthermore, CSF-1R inhibition with pexidartinib (PLX3397) preferentially affected M2-macrophage viability and polarization program disrupting FL-M2 positive crosstalk. In vivo CSF1-R inhibition caused M2 reduction and repolarization towards M1 macrophages and antitumor effect cooperating with anti-CD20 rituximab. In summary, these results support the role of macrophages in FL pathogenesis and indicate that CSF-1R may be a relevant prognostic factor and a novel therapeutic target cooperating with anti-CD20 immunotherapy.

          Related collections

          Most cited references54

          • Record: found
          • Abstract: found
          • Article: not found

          Robust enumeration of cell subsets from tissue expression profiles

          We introduce CIBERSORT, a method for characterizing cell composition of complex tissues from their gene expression profiles. When applied to enumeration of hematopoietic subsets in RNA mixtures from fresh, frozen, and fixed tissues, including solid tumors, CIBERSORT outperformed other methods with respect to noise, unknown mixture content, and closely related cell types. CIBERSORT should enable large-scale analysis of RNA mixtures for cellular biomarkers and therapeutic targets (http://cibersort.stanford.edu).
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            In situ click chemistry generation of cyclooxygenase-2 inhibitors

            Cyclooxygenase-2 isozyme is a promising anti-inflammatory drug target, and overexpression of this enzyme is also associated with several cancers and neurodegenerative diseases. The amino-acid sequence and structural similarity between inducible cyclooxygenase-2 and housekeeping cyclooxygenase-1 isoforms present a significant challenge to design selective cyclooxygenase-2 inhibitors. Herein, we describe the use of the cyclooxygenase-2 active site as a reaction vessel for the in situ generation of its own highly specific inhibitors. Multi-component competitive-binding studies confirmed that the cyclooxygenase-2 isozyme can judiciously select most appropriate chemical building blocks from a pool of chemicals to build its own highly potent inhibitor. Herein, with the use of kinetic target-guided synthesis, also termed as in situ click chemistry, we describe the discovery of two highly potent and selective cyclooxygenase-2 isozyme inhibitors. The in vivo anti-inflammatory activity of these two novel small molecules is significantly higher than that of widely used selective cyclooxygenase-2 inhibitors.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Tumour-associated macrophages as treatment targets in oncology

              Tumour-associated macrophages (TAMs) are key drivers of tumour-promoting inflammation and cancer progression, and are important determinants of responsiveness to a range of therapies. Herein, the authors summarize the roles of TAMs in cancer, and discuss the potential of TAM-targeted therapeutic strategies to complement and synergize with other anticancer treatments.
                Bookmark

                Author and article information

                Contributors
                pperez@clinic.cat
                Journal
                Leukemia
                Leukemia
                Leukemia
                Nature Publishing Group UK (London )
                0887-6924
                1476-5551
                17 March 2021
                17 March 2021
                2021
                : 35
                : 9
                : 2635-2649
                Affiliations
                [1 ]GRID grid.10403.36, Department of Hematology-Oncology, , IDIBAPS, ; Barcelona, Spain
                [2 ]GRID grid.413448.e, ISNI 0000 0000 9314 1427, Centro de Investigación Biomédica en Red-Oncología (CIBERONC), ; Madrid, Spain
                [3 ]GRID grid.265061.6, ISNI 0000 0001 1516 6626, Department of Pathology, , Tokai University, School of Medicine, ; Isehara, Kanagawa Japan
                [4 ]GRID grid.418227.a, ISNI 0000 0004 0402 1634, Gilead Sciences, Inc, ; Foster City, USA
                [5 ]GRID grid.410458.c, ISNI 0000 0000 9635 9413, Hematopathology Unit, Pathology Department, , Hospital Clínic-IDIBAPS, ; Barcelona, Spain
                [6 ]GRID grid.410458.c, ISNI 0000 0000 9635 9413, Department of Hematology, , Hospital Clinic -IDIBAPS, ; Barcelona, Spain
                [7 ]Department of Autoimmune Diseases, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
                [8 ]GRID grid.5841.8, ISNI 0000 0004 1937 0247, University of Barcelona, Medical School, ; Barcelona, Spain
                [9 ]GRID grid.417815.e, ISNI 0000 0004 5929 4381, Present Address: Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, ; Cambridge, UK
                [10 ]GRID grid.415306.5, ISNI 0000 0000 9983 6924, Present Address: Garvan Institute of Medical Research, ; Sydney, Australia
                [11 ]GRID grid.11478.3b, Present Address: Department of Gene Regulation, Stem Cells and Cancer Center for Genomic Regulation (CRG-PRBB), ; Barcelona, Spain
                Author information
                http://orcid.org/0000-0003-3193-9099
                http://orcid.org/0000-0002-4970-8451
                http://orcid.org/0000-0002-4854-3069
                http://orcid.org/0000-0003-0385-3415
                http://orcid.org/0000-0001-9850-9793
                http://orcid.org/0000-0001-7486-8484
                http://orcid.org/0000-0003-3895-5024
                Article
                1201
                10.1038/s41375-021-01201-9
                8410584
                33731849
                8e4e018a-3bd5-4411-a285-e150a040879f
                © The Author(s) 2021

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 18 August 2020
                : 3 February 2021
                : 18 February 2021
                Funding
                Funded by: FundRef https://doi.org/10.13039/501100011033, Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (Spanish Agencia Estatal de Investigación);
                Award ID: SAF2017/88275R
                Award ID: RTI2018-094584-B-I00
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100004587, Ministry of Economy and Competitiveness | Instituto de Salud Carlos III (Institute of Health Carlos III);
                Award ID: CB16/12/00334
                Award Recipient :
                Funded by: FundRef https://doi.org/10.13039/501100002809, Generalitat de Catalunya (Government of Catalonia);
                Award ID: 2017SGR1009
                Award Recipient :
                Categories
                Article
                Custom metadata
                © The Author(s), under exclusive licence to Springer Nature Limited 2021

                Oncology & Radiotherapy
                cancer microenvironment,b-cell lymphoma
                Oncology & Radiotherapy
                cancer microenvironment, b-cell lymphoma

                Comments

                Comment on this article